Current Issue

Mid-July 2024

Hematologic Developments from Around the World

Get updates on the latest breakthroughs in hematology as presented at recent conferences.

Viewpoints

Editor’s Corner

10 Years as a PA: Reflecting on Education Amid a Clinical Site Shortage

Education

Algorithms in Hematology

Using Genomics and BTK Inhibitors in the Treatment of Waldenström Macroglobulinemia

News

In a Different Vein: News from the Blood Journals

Oral Drug Effective for Rare WHIM Syndrome, Approved by FDA

Literature Scan

Straight-to-Transplantation Approach Comparable to Remission Induction in Difficult Acute Myeloid Leukemia Cases

On Location

Asciminib More Effective, Safer Than Frontline Tyrosine Kinase Inhibitors for CML
CARTITUDE-2 Cohort D: Cilta-Cel ± Len Effective for Multiple Myeloma
Phase I Study Shows Long-Term Efficacy of GPRC5D-Directed CAR T-Cell Therapy in Relapsed or Refractory Multiple Myeloma
Rituximab Maintenance in MCL Found Advantageous After Firstline Treatment With Bendamustine-Rituximab
Teclistamab Combination with Daratumumab, Lenalidomide Shows Promising Efficacy, Tolerability in Patients with NDMM
Fewer Patients With CLL/SLL Switch From Zanubrutinib to Another BTKi
Survival Benefit Remains Unclear for Upfront AlloHCT in Untreated Aggressive ATL
Machine Learning Outperforms Full Blood Count in Iron Deficiency Screening
Quad Regimen Reduces Risk of Progression, Death in Older Patients with NDMM
Adenine Base Editors Could Offer Alternative Approach in Beta Hemoglobinopathies Gene Therapies
Patients With Functional High-Risk Multiple Myeloma Show High Response With Ide-Cel
Addition of Avatrombopag to Cyclosporine Can Improve Response Rate in Elderly Patients with Transfusion-Dependent, Non-Severe Aplastic Anemia
Study Identifies Characteristics Related to Bispecific Antibody Response, Resistance
Patients With Low-Grade NHL Experience High Rates of Mental Health Conditions
Venetoclax May Increase Toxicity But Not Efficacy When Added to R-CHOP in Double-Expressor DLBCL
Safety of Oral Azacytidine in Patients With Lower-Risk MDS Consistent With Prior Results
Phase II CAPTIVATE Study: The 5.5-Year Update
Bispecific Antibodies Potent Bridging Therapy to CAR T-Cell Therapy for R/R MM
ATRA-ATO Regimen Demonstrates Superior EFS in Newly Diagnosed, High-Risk Acute Promyelocytic Leukemia
Mosunetuzumab Therapy Elicits High, Durable Responses in Patients With Follicular Lymphoma
Understanding the Prognostic Impact of TP53 Mutations in Chronic Lymphocytic Leukemia

Latest & Greatest

FDA Clears AI Diagnostic Tool for Hematologic Conditions

Data Stream

Mid-July 2024 Data Stream